Takara Bio's RetroNect Used In Australia For Gene Therapy Clinical Trials Of Multiple Myeloma

Tokyo, Dec 18, 2006 (JCN) - Takara Bio has entered into a license and material transfer agreement with the Peter MacCallum Cancer Centre in Melbourne, Australia to supply Takara Bio's RetroNectin for use in a phase I clinical trial of multiple myeloma (MM), which is being conducted by the group of principal investigator Professor Miles Prince. Six patients are expected to be enrolled in this phase I trial.

Back to news